ROGERS ARPI has a total of 16 patent applications. It increased the IP activity by 300.0%. Its first patent ever was published in 2015. It filed its patents most often in United States, Australia and Canada. Its main competitors in its focus markets pharmaceuticals and biotechnology are ANJI PHARMACEUTICALS INC, 7 HILLS INTERESTS LLC and NEURALAB LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 3 | |
#2 | Australia | 2 | |
#3 | Canada | 2 | |
#4 | China | 1 | |
#5 | EAPO (Eurasian Patent Organization) | 1 | |
#6 | EPO (European Patent Office) | 1 | |
#7 | United Kingdom | 1 | |
#8 | Israel | 1 | |
#9 | Republic of Korea | 1 | |
#10 | New Zealand | 1 | |
#11 | Singapore | 1 | |
#12 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Rogers Arpi | 15 |
Publication | Filing date | Title |
---|---|---|
GB202015755D0 | Coronavirus therapy | |
CA3049628A1 | Peptides for therapy | |
EA034876B1 | Use of peptide homodimer in treating diabetes related diseases by oral administration |